Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive liver cancer registry launches to unlock treatment secrets

NCT ID NCT07602504

Knowledge-focused Sponsor: Anhui Provincial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is creating a large database of 2000 people whose cancer has spread to the liver. Researchers will collect information on patients' health, treatments, and outcomes to learn more about the disease and improve future care. No new treatments are being tested; the goal is simply to gather real-world data for research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

May 2036

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This registry targets adult patients with histologically or radiologically confirmed metastatic liver cancer. The population encompasses patients undergoing various standard clinical management strategies, including surgical resection, local ablation, transarterial chemoembolization (TACE), and systemic therapies (chemotherapy, targeted therapy, or immunotherapy).

Ages

18 to 80 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with histologically or radiologically confirmed metastatic liver cancer. 2. Age ≥ 18 years. 3. Patients who have voluntarily signed the informed consent form. 4. Patients with complete baseline clinical data. Exclusion Criteria: 1. Patients with primary liver cancer (e.g., hepatocellular carcinoma). 2. Patients with other malignant tumors that may interfere with the evaluation of liver metastasis. 3. Patients who have previously participated in other interventional clinical trials. 4. Patients with severe cognitive disorders or communication barriers that prevent informed consent. 5. Patients with incomplete or missing key clinical data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer metastatic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm liver cancer liver disorder Liver Neoplasms neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer metastatic Liver cancer Liver diseases Liver metastases Metastases to liver Neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Affiliated Hospital of Qingdao University

    RECRUITING

    Qingdao, Shandong, 266003, China

  • The First Affiliated Hospital of Bengbu Medical University

    NOT_YET_RECRUITING

    Bengbu, Anhui, 230001, China

  • The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

    RECRUITING

    Hefei, Anhui, 230001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.